This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quanterix (QTRX) delivered earnings and revenue surprises of -14.63% and -12.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
by Zacks Equity Research
Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.
Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?
by Zacks Equity Research
Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of 48.39% and 248.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
QuidelOrtho (QDEL) delivered earnings and revenue surprises of 14.55% and 0.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
by Zacks Equity Research
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts Believe Capricor (CAPR) Could Rally 208.09%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
by Zacks Equity Research
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -11.76% and 43.95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Exagen (XGN) delivered earnings and revenue surprises of 6.67% and 7.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Momentum in Capricor (CAPR) Should Keep going
by Zacks Equity Research
Capricor (CAPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Is Capricor Therapeutics (CAPR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Prestige Consumer Healthcare (PBH) Meets Q2 Earnings Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 0% and 0.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 75% and 1.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Verano Holdings Corp. (VRNOF) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Verano Holdings Corp. (VRNOF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Capricor Therapeutics (CAPR) Q3 Earnings Expected to Decline
by Zacks Equity Research
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Could Help Capricor (CAPR) Maintain Its Recent Price Strength
by Zacks Equity Research
Capricor (CAPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes Capricor (CAPR) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Capricor (CAPR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Capricor (CAPR) Have the Potential to Rally 90.16% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Capricor (CAPR) points to a 90.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -9.38% and 11.95%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 46.70% and 1.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
by Zacks Equity Research
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
by Zacks Equity Research
Capricor (CAPR) anticipates announcing top-line results from the Phase 3 HOPE-3 pivotal trial by the fourth quarter of 2024.
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of -181.82% and 50.93%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?